Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Essential Hypertension, Diabetes Mellitus, Type 2
- Main trialPhase 3
- “The purpose of this study is to evaluate safety and efficacy of ATB-1011 and ATB-1012 co-administration in patients with essential hypertension and type II diabetes mellitus”In the company’s words, NCT05573477 on ClinicalTrials.gov
Other drugs for Essential Hypertension
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- Valsartan Oral SolutionShandong New Time Pharmaceutical Co., LTD · Phase 3
- AD-227AAddpharma Inc. · Phase 3
- AD-227BAddpharma Inc. · Phase 3
- QR12000Wuhan Createrna Science and Technology Co., Ltd · Phase 3
- Sacubitril∙ValsartanChong Kun Dang Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 31 Aug 2025 | Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026